Your browser doesn't support javascript.
loading
Expression of circulating microRNA-1 and microRNA-133 in pediatric patients with tachycardia.
Sun, Ling; Sun, Shuo; Zeng, Shaoying; Li, Yufen; Pan, Wei; Zhang, Zhiwei.
Afiliación
  • Sun L; Department of Pediatrics, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangzhou, Guangdong 510080, P.R. China.
  • Sun S; Department of Cardiology, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangzhou, Guangdong 510080, P.R. China.
  • Zeng S; Department of Pediatrics, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangzhou, Guangdong 510080, P.R. China.
  • Li Y; Department of Pediatrics, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangzhou, Guangdong 510080, P.R. China.
  • Pan W; Department of Pediatrics, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangzhou, Guangdong 510080, P.R. China.
  • Zhang Z; Department of Pediatrics, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangzhou, Guangdong 510080, P.R. China.
Mol Med Rep ; 11(6): 4039-46, 2015 Jun.
Article en En | MEDLINE | ID: mdl-25625292
ABSTRACT
Paroxysmal or persistent tachycardia in pediatric patients is a common disease. Certain circulating microRNAs (miRNAs) have been associated with arrhythmia. The present study investigated miRNAs in the plasma of pediatric patients with tachycardia. Forty pediatric subjects were included retrospectively 24 with recurrent sustained tachycardia [seven cases of ventricular tachycardia (VT) and 17 cases of supraventricular tachycardia (SVT)] and 16 healthy controls. Circulating miR­1 and miR­133 in the plasma were detected by fluorescent quantitative polymerase chain reaction. miR­1 levels were significantly decreased in the arrhythmia group compared with those in the controls (P=0.004) whilst miR­133 expression levels were not significantly different between the two groups (P=0.456). Both miR­1 and miR­133 levels showed significant differences between the SVT and VT groups (P=0.004 and P=0.046, respectively), and a significant decrease in miR­1 levels was observed in the SVT group as compared with the controls (P<0.001). No significant difference was observed in the expression levels of miR­133. By contrast, miR­133 levels were significantly increased in the VT group compared with those in the controls (P=0.024), whereas no statistically significant difference was observed in the expression levels of miR­1. Receiver operating characteristic curves showed that 1/miR­1 was significant for the evaluation of tachycardia. Additionally, miR­1 produced enhanced sensitivity and specificity for the evaluation of SVT compared with miR­133, whereas miR­133 was a better marker to assess VT. This study demonstrated that miRNAs may be appropriate markers for pediatric tachycardia; miR­1 levels were decreased in the arrhythmia group compared with those in the healthy controls. Furthermore, patients with SVT had lower miR­1 expression levels while those with VT had higher miR­133 expression levels.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Taquicardia / MicroARNs Límite: Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Mol Med Rep Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Taquicardia / MicroARNs Límite: Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Mol Med Rep Año: 2015 Tipo del documento: Article